Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) FCF Margin (2016 - 2025)

Integra Lifesciences Holdings' FCF Margin history spans 17 years, with the latest figure at 1.24% for Q4 2025.

  • For Q4 2025, FCF Margin fell 602.0% year-over-year to 1.24%; the TTM value through Dec 2025 reached 1.9%, down 345.0%, while the annual FY2025 figure was 1.9%, 345.0% down from the prior year.
  • FCF Margin for Q4 2025 was 1.24% at Integra Lifesciences Holdings, down from 6.4% in the prior quarter.
  • Across five years, FCF Margin topped out at 21.71% in Q2 2021 and bottomed at 10.5% in Q1 2025.
  • The 5-year median for FCF Margin is 5.59% (2024), against an average of 7.1%.
  • The largest annual shift saw FCF Margin skyrocketed 1612bps in 2021 before it plummeted -1178bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 10.32% in 2021, then soared by 73bps to 17.81% in 2022, then tumbled by -52bps to 8.62% in 2023, then crashed by -45bps to 4.78% in 2024, then crashed by -126bps to 1.24% in 2025.
  • Per Business Quant, the three most recent readings for IART's FCF Margin are 1.24% (Q4 2025), 6.4% (Q3 2025), and 2.7% (Q2 2025).